



13:25-13:50 **Targeting KRAS**

David S. Hong

The University of Texas MD Anderson Cancer Center, Professor & Deputy Chair

[Recent Activities]

- Dr. Hong was instrumental in forming one of the largest and most innovative Phase I clinical trial units in the world, with over 1300 patients enrolled in clinical trials in FY2021 and over 300 active ongoing clinical trials.
- Dr. Hong has been the Principal Investigator of over 120 research protocols that involve a wide range of sponsors, including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute.
- Dr. Hong has been involved in the early development of cabozantinib, siltuximab, dabrafenib, trametinib, regorafenib, lenvatinib, larotrectinib, sotorasib, and tesotumab vendotin that have led to FDA approval.

[Research Interests]

- Dr. Hong is an expert on c-Met, NTRK, and KRAS and has led several national trials such as the c-Met amplified, c-Met exon 14 deleted, and NTRK arms of the NCI-MATCH trial